多西他赛加洛铂联合放疗治疗中晚期食管癌的疗效观察

摘要

目的 探讨多西他赛加洛铂联合三维适形放疗治疗中晚期食管癌的疗效与安全性.方法 将76例食管癌患者按照治疗方式的不同分为观察组39例和对照组37例.观察组患者采用三维适形放疗联合多西他赛和洛铂化疗,对照组患者单纯进行三维适形放疗.结果 观察组总有效率为89.7％,对照组有效率为67.5％.观察组有效率显著高于对照组,差异有统计学意义(P＜0.05).观察组恶心呕吐的发生率为61.5％,对照组恶性呕吐的发生率为45.9％,观察组恶性呕吐的发生率显著高于对照组,差异有统计学意义(P＜0.05).2组在骨髓抑制、放射性食管炎和放射性肺炎发生率方面的差异无统计学意义(P＞0.05).观察组患者1、2、3年生存率分别为71.8％、46.2％和35.9％,对照组患者l、2、3年生存率分别为51.4％、29.7％和16.2％.观察组患者1、2、3年生存率显著高于对照组,差异均有统计学意义(P＜0.05).结论 多西他赛加洛铂联合放疗治疗中晚期食管癌疗效显著,不良反应轻,耐受性良好,值得临床推广.%Objective To investigate the curative effect and safety of radiotherapy combined with docetaxe and lobaplatin for advanced esophageal cancer.Methods 76 cases of esophageal cancer,according to the different treatment methods,were divided into the observation group (39 cases)and the control group (37 cases).The observation group used three-dimensional conformal radiotherapy combined with docetaxel and lobaplatin chemotherapy,the control group were treated by three-dimensional conformal radiotherapy only.Results The total effective rate of the observation group was 89.7％,and the control group was 67.5％.The efficiency of the observation group was significantly higher than that of the control group,the difference was statistically significant (P ＜0.05).The incidence of nausea and vomiting in the observation group was 61.5％,the incidence of malignant vomiting in the control group was 45.9％,the incidence of vomiting in the observation group was significantly higher than that of the control group,the difference was statistically significant (P ＜0.05).There was no significant difference between the 2 groups in bone marrow suppression,radiation esophagitis and radiation pneumonia (P ＞ 0.05).1-,2-and 3-year survival rates of the observation group were 71.8％,46.2％ and 35.9％,respectively,and those of the control group were 51.4％,29.7％ and 16.2％ respectively.1-,2-and 3-year survival rates of the observation group were significantly higher than those of the control group,the difference was statistically significant (P ＜ 0.05).Conclusion Docetaxe and lobaplatin combined with radiotherapy in the treatment of advanced esophageal cancer is effective with mild toxicity,it is well tolerated,it is worthy of clinical promotion.